RxDoctor Payments Data

Veretta Deorosan, MD

Internal Medicine · Los Angeles, CANPI 1104997683

Payments from drug & device makers

$1,374in general payments, 2019–2025

Across 35 payments — averaging $39.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$241
  • GSK$148
  • Sanofi$142
  • Lilly USA, LLC$139
  • Gilead$125
  • AbbVie$125
  • plus $454 from 11 others

What the payments were for

  • Food & beverage$1,32997%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,374 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$16,271
Medicare patients
39
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$30,746
JanuviaSitagliptin Phosphate23$25,729
FarxigaDapagliflozin Propanediol15$23,188
EliquisApixaban23$19,958
TrulicityDulaglutide19$17,746
Diclofenac Sodium82$13,988
JardianceEmpagliflozin17$10,570
Albuterol Sulfate HfaAlbuterol Sulfate116$3,194
CrestorRosuvastatin Calcium11$2,600
Amlodipine Besylate260$1,794
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen86$1,530
Gabapentin93$1,412
Atorvastatin Calcium145$1,356
SynthroidLevothyroxine Sodium22$1,112
Metoprolol Succinate60$1,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$44$30,74634 claims
PfizerEliquis$65$19,95823 claims
Lilly USA, LLCTrulicity$139$17,74619 claims
Boehringer IngelheimJardiance$49$10,57017 claims
AbbVieSynthroid$125$1,11222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →